| Literature DB >> 35571727 |
Cunren Chen1, Xixiong Wang2, Changli Liang1, Haiwei Liu1.
Abstract
Objective: Discuss the effectiveness and value of micropower vacuum dressing (MVD) in promoting the healing of I-II grades diabetic foot wounds.Entities:
Year: 2022 PMID: 35571727 PMCID: PMC9106449 DOI: 10.1155/2022/2577601
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Comparison of general information between the two groups.
| Experience group | Control group |
|
| |
|---|---|---|---|---|
| Gender (male/female, no.) | 16/14 | 15/15 | 0.067 | 0.796 |
| Age, mean (SD), years | 51.47 ± 13.13 | 52.33 ± 12.54 | −0.262 | 0.795 |
| Ulcer duration ( | 12.17 ± 6.37 | 13.63 ± 6.22 | −0.902 | 0.371 |
| Ulcer surface area (cm2) | 16.12 ± 5.23 | 17.17 ± 5.66 | −0.748 | 0.458 |
| C-reactive protein (mg/L) | 7.40 ± 4.10 | 8.17 ± 4.40 | −0.699 | 0.488 |
| HbA1C ( | 9.69 ± 1.93 | 10.17 ± 2.04 | −0.936 | 0.353 |
| Insulin injection | 13 (52.0) | 12 (48.0) | 0.069 | 0.793 |
| Combined with neuropathy | 15 (46.9) | 17 (53.1) | 0.067 | 0.796 |
| ABI, mean (SD) | 1.01 ± 0.15 | 0.97 ± 0.12 | 1.130 | 0.263 |
| Wagner classification | ||||
| I | 14 (51.9) | 13 (48.1) | 0.067 | 0.795 |
| II | 16 (48.5) | 17 (51.5) | ||
Comparison of treatment conditions between the two groups.
| Group |
| Healing rate (%) | Reduction rate (%) | Healing time ( | Dressing change times | 1-month recurrence rate (%) |
|---|---|---|---|---|---|---|
| Experience group | 30 | 100 | 82.90 ± 21.18 | 15.27 ± 6.84 | 4.73 ± 1.89 | 0.0 |
| Control group | 30 | 56.7 | 60.60 ± 25.76 | 28.20 ± 12.76 | 13.57 ± 5.59 | 30.0 |
|
| 14.14 | 3.662 | −4.893 | −8.193 | 8.366 | |
|
| 0.001 | 0.001 | <0.001 | <0.001 | 0.004 |
Figure 1Clinical outcome. (a) Just hospitalized. (b) After debridement. (c) After treatment with MVD. (d) 3 days after treatment. (e) 15 days after treatment. (f) 30 days after treatment. (g) Followed up for 1 month.
Comparison of adverse reactions.
| Group |
| Hemorrhage ( | Pain ( | Redness and swelling ( | Incidence of adverse reactions (%) |
|---|---|---|---|---|---|
| Experience group | 30 | 0 | 0 | 2 | 6.7 |
| Control group | 30 | 6 | 7 | 6 | 46.7 |
|
| 4.630 | 5.822 | 1.298 | 10.313 | |
|
| 0.031 | 0.016 | 0.255 | 0.001 |